- Home
- CMMB vs KRKR Comparison
CMMB vs KRKR Comparison
Compare CMMB & KRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- KRKR
- Stock Information
- Founded
- CMMB 2004
- KRKR 2010
- Country
- CMMB Israel
- KRKR China
- Employees
- CMMB N/A
- KRKR N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- KRKR Business Services
- Sector
- CMMB Health Care
- KRKR Consumer Discretionary
- Exchange
- CMMB Nasdaq
- KRKR Nasdaq
- Market Cap
- CMMB 13.7M
- KRKR 12.2M
- IPO Year
- CMMB N/A
- KRKR 2019
- Fundamental
- Price
- CMMB $3.28
- KRKR $5.76
- Analyst Decision
- CMMB Strong Buy
- KRKR
- Analyst Count
- CMMB 2
- KRKR 0
- Target Price
- CMMB $26.50
- KRKR N/A
- AVG Volume (30 Days)
- CMMB 260.4K
- KRKR 28.8K
- Earning Date
- CMMB 11-13-2025
- KRKR 09-26-2025
- Dividend Yield
- CMMB N/A
- KRKR N/A
- EPS Growth
- CMMB N/A
- KRKR N/A
- EPS
- CMMB N/A
- KRKR N/A
- Revenue
- CMMB N/A
- KRKR $30,966,526.00
- Revenue This Year
- CMMB N/A
- KRKR $182.55
- Revenue Next Year
- CMMB N/A
- KRKR N/A
- P/E Ratio
- CMMB N/A
- KRKR N/A
- Revenue Growth
- CMMB N/A
- KRKR N/A
- 52 Week Low
- CMMB $2.39
- KRKR $2.76
- 52 Week High
- CMMB $9.84
- KRKR $21.36
- Technical
- Relative Strength Index (RSI)
- CMMB 59.76
- KRKR 36.73
- Support Level
- CMMB $3.03
- KRKR $5.93
- Resistance Level
- CMMB $3.50
- KRKR $6.32
- Average True Range (ATR)
- CMMB 0.21
- KRKR 0.34
- MACD
- CMMB 0.02
- KRKR -0.21
- Stochastic Oscillator
- CMMB 64.21
- KRKR 0.00
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About KRKR 36Kr Holdings Inc.
36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in PRC.